UNSPSC 51112502: Atrimustine

This classification denotes a nitrogen mustard compound and immunosuppressant with the molecular formula C41H47Cl2NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XC0K09B7K4, chemically known as estradiol 3-benzoate 17-glycolate, 4-(p-(bis(2-chloroethyl)amino)phenyl)butyrate but more generally known as atrimustine, which bears US NIH Compound Identifier 53181. European Medicines Agency schedules Atrimustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05605MIG.

UNSPSC 51112502 Atrimustine is a Commodity code covering a specific chemotherapy agent that state and local governments purchase for use in public health, correctional, and medical facility settings. Atrimustine is a nitrogen mustard derivative used in cancer treatment protocols, and procurement under this code reflects buy patterns for specialized pharmaceutical inventory tied to clinical oncology programs. State and local health departments, correctional health systems, and public hospital networks are the primary issuing bodies soliciting under this code, though activity is episodic and tied to treatment protocols and patient census rather than routine recurring purchases.

The source contains no recent state and local contract opportunities tagged to UNSPSC 51112502. Geographic spread and representative recent solicitations therefore cannot be characterized from posted activity. Atrimustine procurement in the state and local space tends to be absorbed into broader pharmaceutical supply agreements, group purchasing organization contracts, or integrated oncology-program RFPs rather than appearing as standalone commodity buys, which may explain the absence of indexed opportunities under this specific Commodity code.